大行評級丨高盛:石藥集團最壞時刻已過 升目標價至8.74港元
高盛發表報告,石藥集團(1093.HK)最壞時刻已過,故續撐股價前景,更升目標價至8.74港元。報告指出,石藥首季業績疲弱,主要受到去年同期銷售基數高,加上帶量採購及去庫存等不利因素拖累下,令成品藥銷售額跌近三成。不過,目前管理層集中提高股東回報,加上50億美元產品授權合作交易有望完成,因此認爲石藥最壞時刻已過。基於業績最新情況,仍看好石藥,重申“買入”評級,目標價從7.84港元調高11.5%至8.74港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.